Earlier this month, HB1588, proposing mandatory insurance coverage for FDA cleared scalp-cooling costs for cancer patients, cleared another milestone when it passed the Texas House of Representatives following second and third readings. Paxman is proud to have actively supported these efforts along with several Key Opinion Leaders and former patients who have benefitted from the use of Paxman Scalp Cooling during their own cancer treatment. 

Members of Paxman’s private closed Patient Facebook Support Group have also shown significant contributions and support of the bill. Dr. Julie Nangia, assistant professor in the Lester and Sue Smith Breast Center within the NCI-designated Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, who was the Principal Investigator of the Scalp Cooling Alopecia Prevention trial (SCALP) – the first-ever randomized clinical trial to evaluate modern scalp cooling, as part of Paxman’s FDA clearance process – supported the bill in person at the hearing on 30th March 2021. Rep. Jeff Leach introduced the bill along with joint authors: Rep. Victoria Neave, Rep. Justin Holland, Rep. Ken King and, Rep. Kyle Kacal.

In the next step the bill will be heard by The Texas Senate, within the next few weeks and if passed, will require final approval by Texas Governor Greg Abbott. It is anticipated that it would take full effect in September 2021, if approved and signed into law.

“This positive step in the legislative process is very encouraging and we hope the next step will also be a positive stride forwards in providing significantly improved access to scalp cooling during chemotherapy for many patient groups in Texas, where the company now has over 40 locations offering the Paxman Scalp Cooler,” commented Richard Paxman, CEO of Paxman.